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1. Introduction 
2,3-Diphosphoglycerate (2,3-DPG) is the major 
organic phosphate of human erythrocytes. Its role as 
regulator of the oxygenation properties of haemo- 
globin, due to its direct and specific binding with the 
latter, is well known [l-5] . The decrease in the level 
of 2,3-DPG and other intraerythrocytic phospho- 
compounds in blood stored for transfusion is also well 
known [6,7]. Consequently, many studies have been 
carried out with the object of improving our knowledge 
of the factors (whether physiological or not) which 
regulate the amount of this phosphate in human red 
cells under these conditions [g-10] . 
In this communication we present a comparative 
study of some factors which affect the concentration 
of 2,3-DPG. We deal on the one hand with two sulphur 
compounds, tetrathionate and dithionite, oxidizing 
and reducing agents, respectively, which act upon the 
enzymes of the Rapoport Cycle [ 111, catalysts of the 
synthesis (2,3-DPG-mutase; EC 2.7.5.4) or of the 
degradation (2,3-DPG-phosphatase; EC 3.1.3.13) of 
2,3-DPG [9, lo]. Our experiments show that tetra- 
thionate maintains the levels of 2,3-DPG in stored 
blood by inhibiting the 2,3-DPG-phosphatase, while 
dithionite has the contrary effect. On the other hand, 
we deal with a pyrimido-pyrimidine derivative 
(dipyridamole) which has not only a well-defined 
pharmacological action (favouring the flow of oxygen 
to the myocardium), but also maintains the levels of 
endogenous 2,3-DPG [lo] . Experiments with 
dipyridamole show that this compound maintains the 
level of 2,3-DPG in stored blood without affecting the 
activity of these two enzymes. The results have a 
possible practical application in maintaining the 
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2,3-DPG level in blood for transfusion. An analogous 
role has been suggested for dipyridamole as an agent 
preserving the levels of ATP [ 121 . 
2. Materials and methods 
The experiments were carried out with 20 ml of 
heparinized blood from a single donor. 4 ml samples 
were added to sterilized tubes containing 1 ml of a 
solution of 0.07 M citrate and 0.14 M glucose, pH 5.0 
(ACD, formula A, NIH). Two of these tubes also in- 
cluded 5 mM tetrathionate or dithionite by adding 
0.25 ml of 100 mM sodium tetrathionate (K. and K. 
Laboratories, USA) or 100 mM sodium dithionite 
(BDH, England). A third sample included 0.5 mM 
dipyridamole by adding 0.0625 ml of 40 mM dipyri- 
damole hydrochloride (Boehringer and Soehne, 
Ingelheim, Germany). The last sample, added to 
0.25 ml of physiological saline, served as control. The 
final pH in all the samples was 7.0. The mixtures were 
maintained at 4” and aliquots were withdrawn and 
used for the estimation of 2,3-DPG levels and for the 
assay of enzyme activities at zero time and at weekly 
intervals. 
2,3-DPG was determined by Bartlett’s method [ 131 
using chromotropic acid (Merck, Germany) adapted 
to samples of blood by Eaton et al. [ 141. On some 
occasions the enzymatic method of Towne et al. [ 151 
was employed. The activity of the 2,3-DPG-phos- 
phatase was measured using the method developed by 
Harkness et al. [ 161, and that of 2,3-DPG-mutase 
according to method A of Joyce et al. [ 171. The 
preparation of 3-phosphoglycerate free from 2,3-DPG 
necessary for the measurement of the activity of the 
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mutase, was carried out according to Grisolia et al. 
WI. 
3. Results and discussion 
As can be seen in fig. 1, the level of 2,3-DPG in 
human blood is better maintained during storage in the 
presence of tetrathionate. Thus, in about 21 days, the 
2,3-DPG level fell to 50% of its initial value in the 
control but to only 90% in the presence of tetra- 
thionate. Fig. 2 shows the results obtained with rabbit 
blood treated under identical conditions; in this case 
the effect of tetrathionate is also evident from the 
beginning of the period of conservation. The effects 
of dithionite and dipyridamole are shown in fig. 3, 
where treatment with tetrathionate is also included for 
comparison. Dipyridamole maintains the 2,3-DPG 
levels while dithionite has the opposite effect. 
The variation of 2,3-DPG levels under the influence 
of these three compounds could be due to direct 
action upon the enzymes for its synthesis and degrada- 
tion. The activity of 2,3-DPG-phosphatase (fig. 4) in 
ACD human blood is progressively inhibited by 3 
tetrathionate, and activated by dithionite but 
dipyridamole does not alter the activity of this enzyme. 
The values for 2,3-DPG-mutase (data not shown) 
indicate only a slight inhibition in the presence of 
tetrathionate, dipyridamole and dithionite having no 
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Fig. 1. Effect of tetrathionate on the 2,3-DPG levels of ACD 
human blood stored at 4”. Experimental conditions are 
described in the text. 
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Fig. 2. Effect of tetrathionate on the 2,3-DPG levels of ACD 
rabbit blood stored at 4”. Experimental conditions are 
described in the text. 
significant effect. Furthermore, both enzymatic 
activities remained constant in the control blood 
throughout the period of storage. 
Thus the preservation of 2,3-DPG levels by tetra- 
thionate (figs. l-2) appears to be due to the decreased 
activity of the enzyme which degrades it (2,3-DPG- 
phosphatase; fig. 4). The results confirm those 
obtained by Gerlach et al. [lo] and might be explained 
by specific oxidation of -SH groups as has been 
shown to occur in other enzyme systems [ 191. 
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Fig. 3. Comparative ffect of dipyridamole and sulphur com- 
pounds on the 2,3-DPG levels of ACD human blood stored 
at 4”. Experimental conditions are described in the text. 
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Fig. 4. The influence of dipyridamole and sulphur compounds 
on the 2,3-DPGphosphatase activity of ACD human blood 
stored at 4”. The results are expressed in micromoles of 
2,3-DPG hydrolyzed by 0.5 ml of whole blood hemolysate 
during a 2 l-u period of incubation at 38”, pH 7.0, under 
conditions described by Harkness et al. [ 161. 
Dithionite, a strong reducing agent, stimulates 
2,3-DPG-phosphatase (fig. 4) presumably by keeping 
reduced a group needed for its activity (probably -SH). 
This would explain the decrease in the levels of 2,3-DPG 
under its influence (fig. 3). 
Dipyridamole does not act directly upon these 
enzymes, but, nevertheless it also maintains the 
2,3-DPG at a high level (fig. 3); we must, therefore, 
suppose the existence of an indirect mechanism. It 
has been suggested [lo] that dipyridamole induces 
a fall in the concentration of ADP by reducing the 
permeability of erythrocytes for adenosine, thus 
causing a rise of 1,3-diphosphoglycerate (1,3-DPG), 
via phosphoglycerate kinase, and therefore of 2,3-DPG, 
via 2,3-DPG-mutase. 
In summary the results presented here are con- 
sistent, firstly, with the hypothesis of the “in viva” 
regulation of 2,3-DPG by means of ADP [ 10,201 ; 
secondly, indicate that some reduced -SH groups are 
necessary for the activity of 2,3-DPG-phosphatase; 
and lastly, the use of dipyridamole may be useful in 
improving the viability of blood stored for trans- 
fusion. 
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